Virax Biolabs Group Valuation Multiples

Virax Biolabs Group is valued at $3M as of October 2026. In the last 12 months, Virax Biolabs Group revenue was $40K and Virax Biolabs Group EBITDA was ($6M).

Virax Biolabs Group Overview

About Virax Biolabs Group

Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.


Founded

2021

HQ

United Kingdom

Employees

19

Financials (LTM)

Revenue: $40K
EBITDA: ($6M)

Market Cap

$3M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Virax Biolabs Group Financials

Virax Biolabs Group reported last 12-month revenue of $40K and negative EBITDA of ($6M).

In the same LTM period, Virax Biolabs Group generated $39K in gross profit, ($6M) in EBITDA losses, and had net loss of ($5M).


Virax Biolabs Group P&L

In the most recent fiscal year, Virax Biolabs Group reported revenue of $12K and EBITDA of ($5M).

Virax Biolabs Group is unprofitable as of last fiscal year, with gross margin of 62%, EBITDA margin of (43722%), and net margin of (40439%).

See analyst estimates for Virax Biolabs Group
LTMLast FY202320242025202620272028
Revenue$40K$12K$119K$44K$11K
Gross Profit$39K$8K$38K($27K)($7K)
Gross Margin97%62%31%(62%)(69%)
EBITDA($6M)($5M)($6M)($6M)($6M)
EBITDA Margin(14371%)(43722%)(5289%)(13691%)(50682%)
EBIT Margin(12996%)(51515%)(5052%)(13891%)(57972%)
Net Profit($5M)($5M)($6M)($6M)($5M)
Net Margin(12381%)(40439%)(5370%)(14205%)(48469%)
Net Debt-($6M)---

Financial data powered by Morningstar, Inc.

Virax Biolabs Group Stock Performance

Virax Biolabs Group has current market cap of $3M.

Market Cap Evolution


Virax Biolabs Group's stock price is $2.20.

Virax Biolabs Group share price decreased by 0.1% in the last 30 days.

Virax Biolabs Group has an EPS (earnings per share) of $-3.74.

See more trading valuation data for Virax Biolabs Group
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3M0.0%-0.1%--$-3.74

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Virax Biolabs Group Valuation Multiples

Virax Biolabs Group Financial Valuation Multiples

As of October 5, 2026, Virax Biolabs Group has market cap of $3M.

Virax Biolabs Group has a P/E ratio of (0.6x).

LTMLast FY202320242025202620272028
P/E(0.6x)(0.6x)(0.5x)(0.5x)(0.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Virax Biolabs Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Virax Biolabs Group Margins & Growth Rates

Virax Biolabs Group decreased revenue by 100% but net profit grew by 3% in the last fiscal year.

In the most recent fiscal year, Virax Biolabs Group reported gross margin of 62%, EBITDA margin of (43722%), and net margin of (40439%).

See estimated margins and future growth rates for Virax Biolabs Group

Virax Biolabs Group Margins

Last FY202420252026202720282029
Gross Margin62%(62%)(69%)14%
EBITDA Margin(43722%)(13691%)(50682%)(174890%)
EBIT Margin(51515%)(13891%)(57972%)(177040%)
Net Margin(40439%)(14205%)(48469%)(165964%)
FCF Margin(39264%)(13148%)(45414%)(157055%)

Virax Biolabs Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(100%)(63%)(75%)(72%)
Gross Profit Growth(126%)(172%)(72%)(106%)
EBITDA Growth-(5%)(8%)(2%)
EBIT Growth(19%)1%4%(13%)
Net Profit Growth3%(3%)(15%)(2%)
FCF Growth-(15%)(14%)(1%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Virax Biolabs Group Operational KPIs

Virax Biolabs Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Virax Biolabs Group's Rule of 40 is (174961%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Virax Biolabs Group's Rule of X is (175068%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Virax Biolabs Group
LTMLast FY202320242025202620272028
Rule of 40(14471%)(174961%)---
Bessemer Rule of X(14621%)(175068%)---
Revenue per Employee-$0.0M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue67%-22%--
G&A Expenses to Revenue6034%21485%3613%9434%27522%
R&D Expenses to Revenue6969%30092%1470%4395%30382%
Opex to Revenue-51577%5328%14051%57904%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Virax Biolabs Group Competitors

Virax Biolabs Group competitors include NRGene, Bluejay Diagnostics, Lifeline Biotechnologies, 2cureX, Epigenomics, Ludwig Enterprises, Integragen, Curative Biotechnology, Biovica International and Biomerica.

Most Virax Biolabs Group public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
NRGene$3M($975K)0.2x-(0.6x)-
Bluejay Diagnostics-($7M)----
Lifeline Biotechnologies------
2cureX-($478K)--(1.2x)-
Epigenomics$27K($398K)496.5x9.0x(33.8x)(2.9x)
Ludwig Enterprises-($1M)--(2.4x)-
Integragen$14M($225K)----
Curative Biotechnology-($4M)--(1.9x)-

This data is available for Pro users. Sign up to see all Virax Biolabs Group competitors and their valuation data.

Start Free Trial

Virax Biolabs Group VC Funding History

Before going public, Virax Biolabs Group raised $4M in total equity funding, across 4 rounds.

Last private valuation of Virax Biolabs Group was $8M, after raising $2M in March 2020.


Virax Biolabs Group Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-20Series A-$2M$8M-
Sep-18Pre-seed-$1M$4M-
Mar-16Pre-seed-$500K$3M-
Mar-13Pre-seed-$1M$2M-

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Virax Biolabs Group

When was Virax Biolabs Group founded?Virax Biolabs Group was founded in 2021.
Where is Virax Biolabs Group headquartered?Virax Biolabs Group is headquartered in United Kingdom.
How many employees does Virax Biolabs Group have?As of today, Virax Biolabs Group has over 19 employees.
Is Virax Biolabs Group publicly listed?Yes, Virax Biolabs Group is a public company listed on Nasdaq.
What is the stock symbol of Virax Biolabs Group?Virax Biolabs Group trades under VRAX ticker.
When did Virax Biolabs Group go public?Virax Biolabs Group went public in 2022.
Who are competitors of Virax Biolabs Group?Virax Biolabs Group main competitors include NRGene, Bluejay Diagnostics, Lifeline Biotechnologies, 2cureX, Epigenomics, Ludwig Enterprises, Integragen, Curative Biotechnology, Biovica International, Biomerica.
What is the current market cap of Virax Biolabs Group?Virax Biolabs Group's current market cap is $3M.
What is the current revenue of Virax Biolabs Group?Virax Biolabs Group's last 12 months revenue is $40K.
What is the current revenue growth of Virax Biolabs Group?Virax Biolabs Group revenue growth (NTM/LTM) is (100%).
Is Virax Biolabs Group profitable?No, Virax Biolabs Group is not profitable.
What is the current EBITDA of Virax Biolabs Group?Virax Biolabs Group has negative EBITDA and is not profitable.
What is Virax Biolabs Group's EBITDA margin?Virax Biolabs Group's last 12 months EBITDA margin is (14371%).
How many companies Virax Biolabs Group has acquired to date?Virax Biolabs Group hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Virax Biolabs Group has invested to date?Virax Biolabs Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Virax Biolabs Group

Lists including Virax Biolabs Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial